IDEAS home Printed from https://ideas.repec.org/a/bla/jorssc/v68y2019i2p411-425.html
   My bibliography  Save this article

A utility‐based Bayesian phase I–II design for immunotherapy trials with progression‐free survival end point

Author

Listed:
  • Beibei Guo
  • Yeonhee Park
  • Suyu Liu

Abstract

Immunotherapy has been hailed as the biggest breakthrough for treating cancer since the first development of chemotherapy. The new features of immunotherapy make the traditional clinical trial paradigm increasingly inefficient and dysfunctional. We propose a Bayesian phase I–II design for immunotherapy trials called BDFIT to find the optimal biological dose (OBD). We jointly model the toxicity outcome, progression‐free survival (PFS) and immune response. PFS and toxicity are used as the primary end points to determine the OBD, whereas the immune response is used as an ancillary end point to screen out futile doses quickly and to predict the PFS when needed. A utility function is formulated to account for the risk–benefit trade‐off and to quantify the desirability of the dose. During the trial, based on accumulating data, the estimates of the model and dose desirability are continuously updated and used to guide the dose assignment and to select the OBD. The simulation study shows that the BDFIT design has desirable operating characteristics.

Suggested Citation

  • Beibei Guo & Yeonhee Park & Suyu Liu, 2019. "A utility‐based Bayesian phase I–II design for immunotherapy trials with progression‐free survival end point," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 68(2), pages 411-425, February.
  • Handle: RePEc:bla:jorssc:v:68:y:2019:i:2:p:411-425
    DOI: 10.1111/rssc.12288
    as

    Download full text from publisher

    File URL: https://doi.org/10.1111/rssc.12288
    Download Restriction: no

    File URL: https://libkey.io/10.1111/rssc.12288?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bla:jorssc:v:68:y:2019:i:2:p:411-425. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: https://edirc.repec.org/data/rssssea.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.